Input 2021.01.28 15:28 | Revision 2021.01.28 15:50
According to several SK Bioscience officials on the 28th, SK Bioscience is currently reviewing a plan to pay incentives to long-term employees. The HR team is at the stage of devising the timing and amount of incentive payments, and it has not been announced to employees yet.
This system was prepared to prevent employees from leaving after the listing of SK Bioscience. SK Biosciences requested a preliminary examination through NH Investment & Securities, the host company in December of last year, and is expected to be listed on the securities market this year. During the subscription process, executives and employees are allocated employee stock ownership, and immediately after listing, the protection period is at least one year in which the stock cannot be sold. In this case, executives and employees must retire to realize profits by selling stocks.
In fact, SK Biopharm, a subsidiary of SK Group, suffered a massive manpower outflow last year. It is known that since SK Biopharm’s listing in July last year, 70 employees, or 35% of all employees, have signed up.
In response, an official from SK Bioscience said, “Unlike SK BioPharm, which focuses on R&D, SK Bioscience has already generated steady sales, so there is less concern about leaving employees.” Came out.